Core Viewpoint - The collaboration between Four环医药 and AbaloneBio aims to develop innovative obesity treatment drugs by targeting metabolic-related GPCRs, addressing current limitations in weight loss therapies and meeting unmet clinical needs globally [1][2] Group 1: Collaboration Details - Four环医药 has signed a cooperation agreement with AbaloneBio to jointly advance the research and development of next-generation obesity treatments [1] - The project focuses on enhancing energy expenditure safely and effectively while maintaining or increasing muscle mass [1] - AbaloneBio will provide its core technology and platform support in GPCR antibody discovery, while Four环医药 will contribute its research and industrial resources in metabolic diseases [2] Group 2: Strategic Importance - The partnership extends from a previous strategic investment in Abalone, marking a shift from capital involvement to operational execution [2] - This collaboration strengthens Four环医药's innovative positioning in the weight loss sector and accelerates the development of new weight loss and muscle gain therapies [2] - The partnership is also a significant step in deepening Four环医药's focus on GPCR targets, building on prior investments in companies like DJS Antibodies, which has been recognized for its GPCR-targeted antibody development [2]
四环医药(00460)与美国AbaloneBio签署合作协议，联合开发新一代减重增肌创新疗法，进一步深化GPCR靶点领域布局